The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of a combination therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer as a first-line treatment (WJOG9917B, NEWBEAT trial).
 
Yukinori Ozaki
No Relationships to Disclose
 
Koji Matsumoto
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Nihonkayaku; Novartis; Ono Pharmaceutical
Research Funding - AstraZeneca; MSD; Novartis; Ono Pharmaceutical
 
Masato Takahashi
Speakers' Bureau - AstraZeneca; Eisai
 
Toru Mukohara
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Novartis; Taiho Pharmaceutical; Takeda; Teijin Pharma
Research Funding - Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Novartis (Inst)
 
Manabu Futamura
No Relationships to Disclose
 
Norikazu Masuda
Honoraria - AstraZeneca; Chugai Pharma; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
 
Junji Tsurutani
Honoraria - AstraZeneca; Eisai; Kyowa Hakko Kirin; Novartis; Roche; Taiho Pharmaceutical
Consulting or Advisory Role - Asahi Kasei; Eisai
Research Funding - Daiichi Sankyo (Inst); Eisai (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Novartis
 
Kenichi Yoshimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Taiho Pharmaceutical; Takeda
 
Hironobu Minami
Honoraria - Bayer; Bristol-Myers Squibb Japan; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Janssen; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Sanofi; Sanofi; Shire; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Merck Serono; Ono Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Toshimi Takano
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Novartis; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Puma Biotechnology (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)